Climb Research Development vs Net Income From Continuing Ops Analysis
| CLYM Stock | 2.10 0.17 7.49% |
Climb Bio financial indicator trend analysis is way more than just evaluating Climb Bio prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Climb Bio is a good investment. Please check the relationship between Climb Bio Research Development and its Net Income From Continuing Ops accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.
Research Development vs Net Income From Continuing Ops
Research Development vs Net Income From Continuing Ops Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Climb Bio Research Development account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have pay attention.
The correlation between Climb Bio's Research Development and Net Income From Continuing Ops is -0.98. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Climb Bio, assuming nothing else is changed. The correlation between historical values of Climb Bio's Research Development and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Climb Bio are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Research Development i.e., Climb Bio's Research Development and Net Income From Continuing Ops go up and down completely randomly.
Correlation Coefficient | -0.98 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Research Development
Net Income From Continuing Ops
Most indicators from Climb Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Climb Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.As of the 30th of December 2024, Selling General Administrative is likely to drop to about 16.1 M
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 35.7M | 45.1M | 40.3M | 36.5M | Research Development | 23.3M | 26.2M | 15.4M | 20.4M |
Climb Bio fundamental ratios Correlations
Click cells to compare fundamentals
Climb Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.